Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Differential cell counters

This article was originally published in The Gray Sheet

Executive Summary

Automated systems will be reclassified from Class III to Class II with special controls based on information submitted in a reclassification petition by the International Society for Laboratory Hematology, FDA proposes in a May 9 Federal Register notice. FDA had previously rejected a downclassification submission filed by Abbott (1"The Gray Sheet" Jan. 25, 1999, p. 8). The guidance "Automated Differential Cell Counters for Immature or Abnormal Blood Cells" will serve as a special control. Comments are due by Aug. 7
Advertisement

Related Content

Sysmex Sees ADCC Downclassification As Smoothing Path To HPC Indication
Sysmex Sees ADCC Downclassification As Smoothing Path To HPC Indication
Advertisement
UsernamePublicRestriction

Register

MT014858

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel